Germany pharmaceutical company BioNTech, which shot to global prominence after its early coronavirus vaccine, has boosted its cancer drug development by agreeing to buy Chinese firm Biotheus. The Mainz-based group said in a statement on Wednesday it will pay up to $950 million, including an upfront payment of $800 million. The takeover of the Chinese company with around 300 employees is expected to be completed in the first quarter of 2025. With the acquisition, BioNTech will secure full worldwide rights to a drug candidate called BNT327, which is already at an advanced stage of clinical devel…